PDSB · Company research
PDS Biotechnology Corporation Common Stock (PDSB): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors | PDS Biotechnology Corporation announced the appointment of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to its Board of Directors effective October 18, 2026. The three executives bring extensive experience in drug development, commercialization, and regulatory affairs. The appointments follow the resignations of four board members. The company is advancing PDS0301 toward Phase 3 trials in metastatic colorectal cancer and pursuing partnerships for PDS0101. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 1 | 1 |
| PDSB Stock Slides As Shareholders Register 16.5M Shares For Resale - Timothy Sykes | PDSB Stock Slides As Shareholders Register 16.5M Shares For Resale Timothy Sykes | View source ↗ | Timothy Sykes | Oct 18, 2026 | neutral | 0 | 0.6 |
| PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17 - Seeking Alpha | PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow (NASDAQ:PDSB) 2026-10-17 Seeking Alpha | View source ↗ | Seeking Alpha | Oct 17, 2026 | neutral | 0 | 0.6 |
| Pds Biotechnology Stock Price Forecast. Should You Buy PDSB? - StockInvest.us | Pds Biotechnology Stock Price Forecast. Should You Buy PDSB? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? | PDS Biotechnology has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, which increased by 10.6%. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improved earnings outlook. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? | PDS Biotechnology has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates over the past three months, which increased by 10.6%. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improved earnings outlook. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance | PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| PDS Biotechnology Corporation (PDSB) Stock Price | Live Quotes & Charts | NASDAQ - Timothy Sykes | PDS Biotechnology Corporation (PDSB) Stock Price | Live Quotes & Charts | NASDAQ Timothy Sykes | View source ↗ | Timothy Sykes | Oct 10, 2026 | neutral | 0 | 0.6 |
| Nasdaq, S&P 500 Futures Rebound After Fed Rate Hike: NVDA, NBIS, SNAP, SPCX, BE, GNRC Stocks In Focus - Stocktwits | Nasdaq, S&P 500 Futures Rebound After Fed Rate Hike: NVDA, NBIS, SNAP, SPCX, BE, GNRC Stocks In Focus Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| PDSB 261009 2.50C (PDSB261009C2500) Stock Options Chain | Quotes & News - Moomoo | PDSB 261009 2.50C (PDSB261009C2500) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 7, 2026 | neutral | 0 | 0.6 |
| PDS Biotechnology (NasdaqCM:PDSB) Stock Forecast & Analyst Predictions - Simply Wall Street | PDS Biotechnology (NasdaqCM:PDSB) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| PDSB Stock Holds Gains As Volatile Surge Attracts Momentum Traders - StocksToTrade | PDSB Stock Holds Gains As Volatile Surge Attracts Momentum Traders StocksToTrade | View source ↗ | StocksToTrade | Oct 6, 2026 | neutral | 0 | 0.6 |
| PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny - Yahoo Finance | PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny Yahoo Finance | View source ↗ | Yahoo Finance | Sep 18, 2026 | neutral | 0 | 0.6 |
| 80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment - Stock Titan | 80% survived at least two years in a 22-patient trial of PDS Biotech's cancer treatment Stock Titan | View source ↗ | Stock Titan | Sep 8, 2026 | neutral | 0 | 0.6 |
| PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss | PDSB Stock News - Quiver Quantitative | PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss | PDSB Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 13, 2026 | neutral | 0 | 0.6 |
| PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - Benzinga | PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program Benzinga | View source ↗ | Benzinga | Aug 11, 2026 | neutral | 0 | 0.6 |
| PDS0301 Data Show 80% 24-Month Survival With Liver Metastases - Stock Titan | PDS0301 Data Show 80% 24-Month Survival With Liver Metastases Stock Titan | View source ↗ | Stock Titan | Aug 11, 2026 | neutral | 0 | 0.6 |
| Traders are paying attention to the gapping stocks in Tuesday's session. - ChartMill | Traders are paying attention to the gapping stocks in Tuesday's session. ChartMill | View source ↗ | ChartMill | Aug 11, 2026 | neutral | 0 | 0.6 |
| Should I buy PDS Biotechnology (PDSB) - Zacks Investment Research | Should I buy PDS Biotechnology (PDSB) Zacks Investment Research | View source ↗ | Zacks Investment Research | Jun 10, 2026 | neutral | 0 | 0.6 |
| Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - Yahoo Finance | Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher Yahoo Finance | View source ↗ | Yahoo Finance | Jun 10, 2026 | neutral | 0 | 0.6 |
| PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings - Quiver Quantitative | PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | May 13, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.